Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7727 USD | -5.42% | -9.88% | -18.44% |
Financials (USD)
Sales 2024 * | 2.8M | Sales 2025 * | 4M | Capitalization | 56.25M |
---|---|---|---|---|---|
Net income 2024 * | -104M | Net income 2025 * | -110M | EV / Sales 2024 * | 20.1 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 14.1 x |
P/E ratio 2024 * |
-0.59
x | P/E ratio 2025 * |
-0.61
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.19% |
Latest transcript on Kezar Life Sciences, Inc.
1 day | -5.42% | ||
1 week | -9.88% | ||
Current month | -6.28% | ||
1 month | -3.41% | ||
3 months | -18.93% | ||
6 months | +7.72% | ||
Current year | -18.44% |
Managers | Title | Age | Since |
---|---|---|---|
Christopher Kirk
FOU | Founder | 52 | 15-02-18 |
John Fowler
FOU | Founder | 52 | 15-02-18 |
Marc Belsky
DFI | Director of Finance/CFO | 68 | 18-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 16-10-31 |
Graham Cooper
CHM | Chairman | 54 | 17-09-30 |
Michael Kauffman
BRD | Director/Board Member | 60 | 16-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 0.7727 | -5.42% | 1,067,684 |
24-05-09 | 0.817 | -0.49% | 669,717 |
24-05-08 | 0.821 | -2.26% | 620,204 |
24-05-07 | 0.84 | +3.11% | 453,290 |
24-05-06 | 0.8147 | -4.98% | 497,544 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.44% | 56.25M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- KZR Stock